ASUS has released new firmware to patch a critical authentication bypass security flaw impacting several DSL series router models.
Tracked as CVE-2025–59367, this vulnerability allows remote, unauthenticated attackers to log into unpatched devices exposed online in low-complexity attacks that don’t require user interaction.
ASUS has released firmware version 1.1.2.3_1010 to address this vulnerability for DSL-AC51, DSL-N16, and DSL-AC750 router models.
Anthropic reports that a Chinese state-sponsored threat group, tracked as GTG-1002, carried out a cyber-espionage operation that was largely automated through the abuse of the company’s Claude Code AI model.
However, Anthropic’s claims immediately sparked widespread skepticism, with security researchers and AI practitioners calling the report “made up” or the company of overstating the incident.
“I agree with Jeremy Kirk’s assessment of the Anthropic’s GenAI report. It’s odd. Their prior one was, too,” cybersecurity expert Kevin Beaumont posted on Mastodon.
Hardware accessory giant Logitech has confirmed it suffered a data breach in a cyberattack claimed by the Clop extortion gang, which conducted Oracle E-Business Suite data theft attacks in July.
Logitech International S.A. is a Swiss multinational electronics company that sells hardware and software solutions, including computer peripherals, gaming, video collaboration, music, and smart home products.
Today, Logitech filed a Form 8-K with the U.S. Securities and Exchange Commission, confirming that data was stolen in a breach.
Natural gas—one of the planet’s most abundant energy sources—is primarily composed of methane, ethane, and propane. While it is widely burned for energy, producing greenhouse gas emissions, scientists and industries have long sought ways to directly convert these hydrocarbons into valuable chemicals. However, their extreme stability and low reactivity have posed a formidable challenge, limiting their use as sustainable feedstocks for the chemical industry.
Now, a team led by Martín Fañanás at the Center for Research in Biological Chemistry and Molecular Materials (CiQUS) at the University of Santiago de Compostela has developed a groundbreaking method to transform methane and other natural gas components into versatile “building blocks” for synthesizing high-demand products, such as pharmaceuticals. Published in Science Advances, this advance represents a critical leap toward a more sustainable and circular chemical economy.
For the first time, the CiQUS team successfully synthesized a bioactive compound—dimestrol, a non-steroidal estrogen used in hormone therapy—directly from methane. This achievement demonstrates the potential of their methodology to create complex, high-value molecules from a simple, abundant, and low-cost raw material.
Cells have an internal skeleton that maintains their structure and also drives their movement. Known as the cytoskeleton, this scaffold is composed of a network of dynamic filaments made of a protein called actin.
Given how important these structures are, alterations in the proteins that work together to build and control the actin cytoskeleton are often lethal or cause severe effects. For example, children born with mutations in the ARPC5 protein, which is part of the Arp2/3 complex, experience immunodeficiency and a high risk of fatal sepsis in early life.
“This is a rare and devastating condition, and until recently, it wasn’t clear how these mutations lead to such severe illness,” says Michael Way, who runs the Cellular Signaling and Cytoskeletal Function Laboratory at the Crick. “The only known effective treatment would involve early bone marrow transplantation to replace the faulty immune cells with ones which have a healthy actin cytoskeleton.”
The “Petralona Man,” or “Petralona Archanthropus” is a for 700,000 years old human skull found in 1959. Since then, scientists have tried to locate the origin of this skull, which has created tremendous controversy.
The skull, indicating the oldest human “Europeoid” (presenting European traits), was embedded in a cave’s wall in Petralona, near Chalkidiki in Northern Greece.
A shepherd mistakenly found the cave, dense with stalactites and stalagmites. The cave and skull study was assigned to Dr. Aris Poulianos, an anthropologist specialist, member of UNESCO’s International Union of Anthropology and Ethnology, and president of the Anthropological Association of Greece.
After numerous successful trials in the model, the team sought to demonstrate what the microrobot could achieve under real clinical conditions. First, they were able to demonstrate in pigs that all three navigation methods worked and that the microrobot remains clearly visible throughout the entire procedure. The investigators then navigated microrobots through the cerebral fluid of a sheep.
“This complex anatomical environment has enormous potential for further therapeutic interventions, which is why we were so excited that the microrobot was able to find its way in this environment too,” Landers noted. “In vivo experiments conducted with an ovine model demonstrated the platform’s ability to operate within anatomically constrained regions of the central nervous system,” the investigators stated in their paper. “Furthermore, in a porcine model, all locomotion strategies were validated under clinical conditions, confirming precise microrobot navigation within the cerebrovascular system and highlighting the system’s compatibility with versatile in vivo environments.”
In addition to treating thrombosis, these new microrobots could also be used for localized infections or tumors. At every stage of development, the research team has remained focused on their goal, which is to ensure that everything they create is ready for use in operating theaters as soon as possible. The next goal is to look at human clinical trials. “The use of materials that have been FDA approved for other intravascular applications, coupled with the modular design of the robotic platform, should simplify translation and adaptability to a range of clinical workflows,” the authors concluded. Speaking about what motivates the whole team, Landers said, “Doctors are already doing an incredible job in hospitals. What drives us is the knowledge that we have a technology that enables us to help patients faster and more effectively and to give them new hope through innovative therapies.”
Biology needs the same kind of substrate. Without it, we are still guessing. With it, discovery starts to look predictable by design.
Drug development still leans on animal models and small patient cohorts to make billion-dollar bets. Those proxies teach us something, but they do not teach how a molecule behaves across the complexity of human biology. That is why nine out of ten drugs that succeed in animals fail in human clinical trials.
Biology needs an environment that gives intelligence the same systematic feedback that data centers gave to computation. That is what biological data centers provide. Robotic systems that sustain tens of thousands of standardized human tissues at once. Tissues that are vascularized and immune competent, clinically indistinguishable from patient biopsies under blinded review. Tissues that can be dosed, that bleed, that heal.
